[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-nasopharyngeal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-nasopharyngeal-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,73,99,133,157,181,203,223,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100518340","phase-2-testing-the-addition-of-bms-986016-relatlimab-to-the-usual-immunotherapy-after-initial-treatment-for-recurrent-or-metastatic-nasopharyngeal-cancer-100518340",false,"NCT06029270","Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent\u002FMetastatic Nasopharyngeal Carcinoma (REMAIN)","Inclusion Criteria:\n\n* PRIOR TO STEP 1 REGISTRATION:\n* Pathologically (histologically or cytologically) proven diagnosis of nasopharyngeal carcinoma (NPC) that has recurred locoregionally and\u002For is present at distant sites. Patients who present with metastatic disease (de novo) at diagnosis are also eligible. For locoregional recurrence, the disease must not be amenable to potentially curative surgery or re-irradiation. Eligible patient must have the following characteristics:\n\n  * Tumor showing (histological\u002Fcytological) Epstein-Barr encoded ribonucleic acid (EBER)-positivity (e.g., In situ hybridization, immunohistochemistry) or\n  * A known history of detectable plasma EBV DNA (via a polymerase chain reaction \\[PCR\\]-based assay) at any time point since the initial diagnosis of NPC.\n* Measurable disease as defined by RECIST 1.1 criteria. Lesion(s) that have been irradiated previously can be counted as measurable as long as radiological progression after the prior radiation therapy has been demonstrated.\n\n  * Contrast enhanced CT scan of the chest. The contrast enhanced CT component of a whole-body PET-CT is also acceptable. The plain (non-contrast) CT component of a PET-CT is not acceptable.\n  * CT the abdomen and pelvis, if clinically indicated (diagnostic quality with contrast, unless contraindicated).\n  * Patients with known locoregional disease must have contrast enhanced MRI or CT of the nasopharynx and neck as this disease site(s) may be assessed as target lesions. For patients without known locoregional disease, imaging of the nasopharynx and neck is optional.\n  * Symptomatic and active brain metastases and\u002For leptomeningeal metastasis on CT and\u002For MRI imaging: Patients who have prior therapies for brain and leptomeningeal metastasis or cord\u002Fcauda compression who are clinically stable for \\>= 2 months prior to registration and have discontinued systemic steroids therapy (\\> 10 mg\u002Fday prednisone or equivalent) \\> 4 weeks prior to registration are eligible.\n  * Patients with base of skull involvement by NPC are allowed unless their disease is directly invading the brain parenchyma, associated with clinical symptoms and\u002For significant vasogenic edema on radiological imaging.\n* Age \\>= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status of 0-2.\n* Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal.\n* Absolute neutrophil count (ANC) \\>= 1500 cells\u002Fmm\\^3.\n* Platelets \\>= 100,000 cells\u002Fmm\\^3.\n* Hemoglobin (Hgb) \\>= 8.0 g\u002FdL (Transfusion is accepted. Erythropoietin dependency not accepted.).\n* Total bilirubin =\\\u003C 1.5 × institutional upper limit of normal (ULN) or direct bilirubin =\\\u003C ULN for patients with total bilirubin levels \\> 1.5 × ULN. Patients with known Gilbert's disease who have serum bilirubin level =\\\u003C 3 × ULN may be enrolled.\n* Alanine transaminase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) =\\\u003C 3 × ULN (=\\\u003C 5 × ULN for patients with liver metastases).\n* Serum creatinine =\\\u003C 1.5 × ULN or calculated creatinine clearance (CrCl) based on Cockcroft-Gault equation \\>= 30 mL\u002Fmin for patients with serum creatinine levels \\> 1.5 × ULN. Cisplatin or carboplatin may be used at the discretion of the investigator - except for patients with CrCl between 30-50 mL\u002Fmin, for whom carboplatin should be used instead of cisplatin. CrCl must be \\> 50 mL\u002Fmin for cisplatin to be used.\n* Albumin-adjusted calcium level based on corrected calcium equation =\\\u003C 1.5 × ULN (patients are allowed to have treatment for hypercalcemia prior to starting treatment).\n* No prior systemic treatment of palliative intent for recurrent\u002Fmetastatic (R\u002FM) NPC including cytotoxic chemotherapy. Prior treatment for non-recurrent and non-metastatic NPC is allowed. Systemic therapy given prior to curative intent re-irradiation or surgery is allowed for potentially curable locoregional recurrence.\n* No prior treatment with a PD-1 inhibitor (except if given as adjuvant or neoadjuvant therapy for NPC), PD-L1 inhibitor, anti-PD-L2 inhibitor, LAG-3 inhibitor, CTLA-4 inhibitor (except if given as adjuvant or neoadjuvant therapy for non-recurrent and non-metastatic NPC), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.\n* The interval between the last dose of curative-intent treatment for non-recurrent, non-metastatic NPC, including definitive radiotherapy (RT) and\u002For induction, concurrent, or adjuvant chemotherapy and recurrence must be ˃ 6 months.\n* Clinically significant toxicities from any prior systemic therapy or radiotherapy must have resolved to grade 0 or 1 as per National Cancer Institute (NCI) CTCAE v 5.0 - except alopecia, dry mouth, dysgeusia, dysphagia, and fatigue. Patients with a history of grade 3-4 cisplatin related neuropathy must have recovered to grade 0-2 prior to registration. Patients with a history of hearing impairment, or ototoxicity from prior cisplatin, of any grade are allowed.\n* No prior palliative RT within 30 days prior to registration unless the irradiated site(s) are not the target lesions. The irradiated site(s) also must not be the only sites of measurable recurrent disease.\n* No major surgical procedures within 30 days prior to registration.\n* No history of unstable angina requiring hospitalization within the last 6 months.\n* No history of myocardial infarction within the last 6 months.\n* New York Heart Association Functional Classification II or better (New York Heart Association \\[NYHA\\] Functional Classification III\u002FIV are not eligible). Patients with symptomatic coronary artery disease, congestive heart failure or a known history of having a left ventricular ejection fraction \\\u003C 50% must be stably controlled with medication in the opinion of the treating physician, in consultation with a cardiologist if appropriate.\n* No prior history of myocarditis.\n* No active infection requiring IV antibiotics, IV antiviral, or IV antifungal treatments at the time of study registration.\n* No history of (non-infectious) pneumonitis that required steroids or current pneumonitis requiring steroids and\u002For immunosuppressive therapy, idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), or idiopathic pneumonitis.\n* No history of multi-drug resistant mycobacterium tuberculosis (TB) or active TB, as defined by systemic treatment received =\\\u003C 2 years prior to registration. Note: Patients who had a history of treated TB ˃ 2 years prior to registration are allowed.\n* No prior solid organ transplant or bone marrow transplant.\n* No conditions requiring systemic treatment with either immunosuppressive doses of corticosteroids (\\> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids and adrenal replacement doses \\\u003C 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Steroid premedication for the prophylaxis of CT contrast-related allergies is allowed. The use of dexamethasone as an anti-emetic premedication prior to chemotherapy is also allowed.\n* No active autoimmune disease requiring systemic treatment (i.e., disease modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. These may include (but not limited to) patients with a history of immune-related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, autoimmune hepatitis, glomerulonephritis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome.\n\n  * Note: Patients are permitted to enroll if they have vitiligo; type I diabetes mellitus; hypothyroidism, pituitary or adrenal insufficiency requiring only hormone replacement; alopecia; and\u002For psoriasis not requiring systemic treatment. Conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* No prior live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist \\[registered trademark\\]) are live attenuated vaccines and are not allowed. Coronavirus disease 2019 (COVID-19) vaccines that are approved by the local drug regulatory authority of the participating region are allowed.\n* No known history of grade 3-4 allergic reaction or hypersensitivity reaction to cisplatin, carboplatin, or gemcitabine.\n* No known history of grade 4 hypersensitivity (or infusion) reaction to any monoclonal antibody. Patients who had prior grade 3 hypersensitivity (or infusion) reaction but could tolerate resumption of the antibody treatment after appropriate pre-medication are eligible.\n* PRIOR TO STEP 2 REGISTRATION:\n* Collection of plasma EBV DNA at baseline is mandatory for all patients prior to Step 2 registration and induction treatment.\n\n  * Note: Submission of the baseline sample will be batch shipped.\n* PRIOR TO STEP 3 REGISTRATION\u002FRANDOMIZATION: PATIENTS WITHOUT PROGRESSIVE DISEASE (PD) ONLY:\n* All patients must have received minimum of 3 cycles, and up to a maximum of 6 cycles of induction treatment within 20 weeks from cycle 1, day 1 of induction treatment (i.e., patients must have completed all induction treatment within 20 weeks from cycle 1 day 1, including the treatment breaks). Patients must have completed 6 cycles of induction treatment, except in the following circumstances:\n\n  * Significant dose delays as a result of treatment-related toxicities.\n  * Intercurrent illness(s), that rendered the patient unable to continue induction treatment.\n  * Note: If a patient received \\\u003C 6 cycles of induction treatment for reasons other than the above circumstances, they will not be eligible for randomization.\n* A CT scan within 30 days prior to Step 3 registration\u002Frandomization is required. If the most recent scan performed is not within this time frame, a repeat scan is required to assess response.\n* Did not meet any criteria that result in permanent discontinuation of study treatment during induction treatment phase.\n* Must meet the criteria for starting\u002Fresuming a new cycle of maintenance treatment.\n* Did not experience any nivolumab-related autoimmune toxicities that would result in permanent discontinuation of nivolumab during the induction treatment phase.\n* Collection of the plasma EBV DNA post-induction treatment is mandatory.\n\n  * Note: Submission of the post-induction sample will be batch shipped.","ALL","18 Years",{"count":19,"type":20},156,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.",[26,27,28],"Metastatic Nasopharyngeal Carcinoma","Recurrent Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma AJCC v8","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":33},"2024-07-15",{"date":37,"type":20},"2029-04-30",{"name":39,"class":40},"National Cancer Institute (NCI)","NIH",88,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100355429","phase-3-pd-1-antibody-combined-with-chemoradiotherapy-in-recurrent-nasopharyngeal-carcinoma-patients-100355429","NCT03907826","PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients","PD-1 Antibody Combined With Chemoradiotheapy vs. Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients: a Multicenter, Randomised Controlled, Phase III Clinical Trial","Inclusion Criteria:\n\n* Diagnosed as local recurrence ± regional recurrence after ≥1 year of radical treatment;\n* Not suitable for surgery;\n* Newly histologic diagnosis of NPC (WHO II\u002FIII);\n* Clinical stage rII-IVa (AJCC\u002FUICC 8th);\n* ECOG 0-1 point;\n* No treatment to rNPC, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;\n* No contraindications to immunotherapy or radiotherapy;\n* Adequate marrow function: WBC count ≥ 3×10E9\u002FL, NE count ≥ 1.5×10E9\u002FL, HGB ≥ 90g\u002FL, PLT count ≥ 100×10E9\u002FL;\n* Adequate liver function: ALT\u002FAST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;\n* Adequate renal function: BUN\u002FCRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Take effective contraceptions during and two months after treatment;\n* Patients must be informed of the investigational nature of this study and give written informed consent.\n\nExclusion Criteria:\n\n* Treated with anti-tumor Chinese medicine treatment;\n* Have recurrence with local necrosis;\n* Have ≥G3 late toxicities, except for skin, subcutaneous tissue or mucosa;\n* Unexplained fever \\> 38.5 ℃, except for tumor fever;\n* Treated with ≥ 5 days antibiotics one month before enrollment;\n* Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy); Have a known history of human immunodeficiency virus (HIV), active Hepatitis B (HBV-DNA ≥10E4copiers\u002Fml) or hepatitis C virus (HCV) antibody positive; Have previously treated with PD-1 antibody or other immunotherapy for PD-1\u002FPD-L1 pathway;\n* Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment;\n* Have known allergy to large molecule protein products or any compound of study therapy;\n* Pregnant or breastfeeding;\n* Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma;\n* Have received a live vaccine within 30 days of planned start of study therapy Has psychiatric drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial;\n* Any other condition, including mental illness or domestic\u002Fsocial factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.","70 Years",{"count":51,"type":20},212,[53],"PHASE3","This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.",[27],[57,58,59,60,61],"PD-1 antibody","Intensity-modulated Radiation Therapy","Efficacy","Adverse effect","chemotherapy","2026-05-06",{"date":64,"type":33},"2026-05-07",{"date":66,"type":33},"2020-03-01",{"date":68,"type":20},"2028-12",{"name":70,"class":71},"Sun Yat-sen University","OTHER",12,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":98},"100395145","plasma-radiofrequency-ablation-at-low-temperature-versus-electrocautery-block-resection-at-high-frequency-for-localized-recurrent-nasopharyngeal-carcinoma-100395145","NCT04425265","Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma","A Randomized Controlled Trial of Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma.","Inclusion Criteria:\n\n1. At least 6 months disease free interval (defined as duration between the initial course of radiotherapy and recurrence)\n2. Histopathologically diagnosed with undifferentiated or differentiated, nonkeratinizing nasopharyngeal carcinoma.\n3. Resectable recurrent nasopharyngeal carcinoma: rT1-3N0-3M0 A) The tumor is confined to the nasopharyngeal mucosa, or the surface of the parapharyngeal space, or the bottom wall of the sphenoid sinus, and is more than 0.5cm away from the internal carotid artery B) The cervical lymph node lesions do not infiltrate the cervical spine, brachial plexus, cervical muscles, and internal carotid artery.\n4. Age: 18-70 years old.\n5. Subjects must sign an informed consent form.\n\nExclusion Criteria:\n\n1. Karnofsky score (KPS)≤70.\n2. Has known Subjects with other malignant tumors.\n3. Has seriously mental disease.\n4. Uncontrolled clinically significant heart disease and Pulmonary dysfunction.\n5. Pregnancy or breast feeding.",{"count":81,"type":20},500,[83],"NA","This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a randomized controlled trial of plasma radiofrequency ablation at low temperature versus electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma. If the hypothesis is confirmed, it is expected to provide a convenient choice for the surgical treatment of localized recurrent nasopharyngeal carcinoma.",[86,27],"Surgery",[88,89,90],"recurrent nasopharyngeal carcinoma","Plasma Radiofrequency Ablation","Electrocautery Block Resection","2026-05-05",{"date":93,"type":33},"2026-05-08",{"date":95,"type":33},"2020-06-30",{"date":68,"type":20},{"name":70,"class":71},3,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100611947","phase-1-integrating-allogeneic-nk-cells-in-high-risk-advanced-stage-iii-iv-nasopharyngeal-cancer-patients-100611947","NCT07247201","Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients","Phase 1\u002F2 Trial Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients","AlloNK1","Inclusion Criteria:\n\n* Diagnosed with NPC Stage III-IVA\u002FB (T1-4, N1-3, M0)\n* Able to tolerate convectional CRT\n* Detectable EBV level at diagnosis\n* Adequate organ function ANC ≥ 1500\u002FµL Platelet count ≥ 100,000\u002FµL Creatinine clearance ≥60ml\u002Fminute Total bilirubin ≤ 1.5 x upper limit normal (ULN) AST ≤ 2 x upper limit normal ALT ≤ 2 x upper limit normal\n* ECOG performance status of 0-1\n\nExclusion Criteria:\n\n* History of Autoimmune Disease or any condition resulting in immunocompromised state (e.g., Drug induced)\n* ECOG performance status above or equal to 2\n* Poor Organ Function\n* Lactating or pregnant\n* Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study.","21 Years","80 Years",{"count":110,"type":20},31,[112,23],"PHASE1","This clinical trial aims to determine whether Natural Killer (NK) cell therapy administered in combination with concurrent chemoradiotherapy (CRT) can reduce recurrence in patients with advanced nasopharyngeal cancer (NPC), and to identify the highest safe and tolerable dose of allogeneic NK cells. Allogeneic NK cells, derived from healthy donors, have demonstrated good tolerability in cancer patients.\n\nThe primary research questions are:\n\n1. What is the maximum tolerated dose (MTD) of allogeneic NK cells when administered with CRT in NPC patients?\n2. Can the addition of allogeneic NK cells to standard CRT reduce the proportion of NPC patients with detectable plasma EBV-DNA from 30% to 10%?\n\nPhase 1: Participants will receive one of five escalating doses of allogeneic NK cells with CRT to determine the MTD.\n\nPhase 2: Participants will receive the established MTD NK dose together with CRT.\n\nParticipants will undergo regular safety monitoring, side-effect assessment, measurement of plasma EBV-DNA levels, and surveillance for disease recurrence.",[115,116,27,117],"Nasopharyngeal Carcinoma (NPC)","Minimal Residual Disease","Maximum Tolerated Dose",[119,120,121,117],"Advanced Nasopharyngeal Cancer","Epstein-Barr Virus DNA","Allogeneic NK Cells","NOT_YET_RECRUITING","2026-03-24",{"date":125,"type":33},"2026-03-30",{"date":127,"type":20},"2026-04",{"date":129,"type":20},"2026-09",{"name":131,"class":71},"Singapore General Hospital",1,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100624644","proton-therapy-for-recurrent-nasopharyngeal-carcinoma-100624644","NCT07412314","Proton Therapy for Recurrent Nasopharyngeal Carcinoma","A Prospective Phase II Clinical Study of Proton Therapy for Recurrent Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Non-metastatic squamous cell carcinoma of the nasopharynx with biopsy confirmation, at stage ≥ T2b and\u002For with positive lymph nodes, (2) Pathological type WHO I-III\n2. PS score (according to Eastern Cooperative Oncology Group (ECOG) standard) 0-1.\n\n   Age ≥ 18 years.\n3. Expected survival period ≥ 6 months\n4. Before treatment, evaluate the tumor range and size of the patient.\n5. Nutritional and general physical condition must be able to tolerate the recommended radiotherapy and chemotherapy.\n\nExclusion Criteria:\n\n1. Evidence of distant metastasis in stage IVc\n2. Patients with isolated recurrence of cervical lymph nodes;\n3. Patients have participated in other interventional trials for tumors\n4. Having suffered from other malignant tumors within 5 years (excluding melanoma skin cancer) or tumors originating from the head and neck region Untreated active infections",{"count":141,"type":20},52,[83],"The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and retrospective studies, lacking high-level evidence-based medical evidence. The conduct of this study will explore the safety and efficacy of intensity-modulated proton radiotherapy for recurrent NPC and provide more high-quality evidence-based medical evidence for proton therapy of recurrent cancer.",[27],[146,88],"proton therapy","2026-03-05",{"date":149,"type":33},"2026-03-09",{"date":151,"type":33},"2025-03-10",{"date":153,"type":20},"2028-03-10",{"name":155,"class":71},"Guangzhou Concord Cancer Center",2,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100599745","watch-and-wait-after-immunochemotherapy-in-locally-recurrent-nasopharyngeal-carcinoma-100599745","NCT07088484","Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","Watch-and-Wait Strategy in Patients With Objective Response After Immuno-chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma: A Prospective Multicenter Observational Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex.\n2. Treatment-naïve patients with newly diagnosed metastatic nasopharyngeal carcinoma (NPC).\n3. Receiving immunotherapy. (or Treated with immunotherapy)\n4. At least one measurable tumor lesion according to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1.\n5. Adequate organ function.\n6. Signed and dated informed consent form indicating that the patient (or legally authorized representative) has been informed of all pertinent aspects of the study.\n7. Patients willing and able to comply with scheduled visits and study procedures.\n\nExclusion Criteria:\n\n1. Patients with distant metastasis of nasopharyngeal carcinoma.\n2. Patients who have not received immunotherapy or chemotherapy. (Alternatively: No prior immunotherapy or chemotherapy.)\n3. History of another active malignancy within the past 5 years, except for malignancies with a negligible risk of metastasis or death (e.g., expected 5-year overall survival \\>90%) or malignancies treated with curative intent and with no evidence of disease (e.g., adequately treated carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin, localized prostate cancer treated with curative intent, ductal carcinoma in situ of the breast treated surgically with curative intent).\n4. Lack of capacity to provide informed consent.",{"count":165,"type":20},50,"OBSERVATIONAL","The purpose of this study is to compare chemotherapy plus immunotherapy with immunochemotherapy combined subsequent locoregional radiotherapy in recurrent nasopharyngeal carcinoma (NPC), in order to confirm the value of immunotherapy and chemotherapy in recurrent NPC patients.",[27],[170],"locally recurrent nasopharyngeal carcinoma, watch-and-wait strategy, immuno-chemotherapy, low-intensity maintenance treatment","2025-07-20",{"date":173,"type":33},"2025-07-28",{"date":175,"type":20},"2025-08-01",{"date":177,"type":20},"2027-09-01",{"name":179,"class":180},"Fujian Cancer Hospital","OTHER_GOV",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":186,"conditions":192,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100533612","phase-3-adjuvant-vs-surgery-only-in-early-stage-recurrent-npc-100533612","NCT06228079","Adjuvant vs Surgery Only in Early-stage Recurrent NPC","Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pathologically diagnosed with recurrent nasopharyngeal carcinoma;\n2. Stage rT1 or rT2(superficial parapharyngeal space, distance to internal carotid artery \\>5mm)or rT3 (confined to the bottom wall of the sphenoid sinus),according to AJCC 8th edition;\n3. Cervical lymph node metastasis can be controlled locally\n4. Age 18 to 75 years;\n5. Without distant metastasis;\n6. Informed consent forms signed;\n7. ≥6months from the accomplishment of radiation to recurrence\n8. previously radiotherapy for only 1 course;\n9. ECOG score 0-2 and can tolerate chemotherapy and immunotherapy\n10. Sufficient organ function;\n11. Undergone endoscopic surgery with negative pathological margin;\n\nExclusion Criteria:\n\n1. Participation in other interventional clinical trials;\n2. Uncontrolled illnesses which will interfere with the ability to undergo therapy;\n3. Suffering from another or multiple malignancy within 5 years (excluding fully treated basal cell or skin squamous cell carcinoma, cervical carcinoma in situ);\n4. Any contradiction to immune and chemotherapy;\n5. With serious autoimmune disease;\n6. Currently usage of immunosuppressive agents or systemic glucocorticoid therapy (dosage\\>10mg\u002Fday prednisone or other glucocorticoids), and continuing to use them within 2 weeks before the first administration of trial drugs;\n7. Severe allergic reactions to other monoclonal antibodies;\n8. History of radioactive particle planting;\n9. Vaccination with live vaccine within 4 weeks prior to initial administration or possibly during the study period;\n10. Female patients who are at pregnancy or lactation;\n11. Other situations that the researchers believe are not suitable for enrollment","75 Years",{"count":190,"type":20},176,[53],[27],"2025-07-01",{"date":195,"type":33},"2025-07-04",{"date":197,"type":33},"2024-06-25",{"date":199,"type":20},"2028-06-30",{"name":201,"class":71},"Eye & ENT Hospital of Fudan University",7,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":202},"100534159","phase-3-neoadjuvant-vs-adjuvant-in-locally-advanced-recurrent-npc-100534159","NCT06235203","Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC","Neoadjuvant-Adjuvant Versus Adjuvant-Only Therapy Combined With Endoscopic Surgery in Advanced Recurrent Nasopharyngeal Carcinoma:A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pathologically diagnosed with recurrent nasopharyngeal carcinoma;\n2. Resectable disease staging rT2 (deep parapharyngeal space, or distance to the internal carotid ≤5mm) or rT3 (excluding the lesions confined to the basal wall of sphenoid sinus), rT4, according to AJCC 8th edition;\n3. Cervical lymph node metastasis can be controlled locally;\n4. Aged 18 to 75 years;\n5. Informed consent forms signed to participate in the trial;\n6. Without distant metastasis;\n7. ≥6months from the accomplishment of radical radiation to recurrence\n8. previously only 1 course of radiotherapy;\n9. Sufficient organ function;\n10. ECOG score 0-2 and can tolerate surgery,chemotherapy and immunotherapy.\n\nExclusion Criteria:\n\n1. Participate in other interventional clinical trials;\n2. Uncontrolled illnesses that interfere with the therapy;\n3. Suffering from another or multiple malignancy within 5 years (excluding fully treated basal cell or skin squamous cell carcinoma, cervical carcinoma in situ, etc.);\n4. Any contradiction to surgery;\n5. With serious autoimmune disease;\n6. The patient is currently using immunosuppressive agents or systemic hormone therapy to achieve immunosuppressive effects (dosage\\>10mg\u002Fday prednisone or other glucocorticoids), and continues to use them within 2 weeks before the first administration;\n7. Severe allergic reactions to other monoclonal antibodies;\n8. History of radioactive particle planting;\n9. Vaccination with live vaccine within 4 weeks prior to initial administration or possibly during the study period;\n10. Female patients who are at pregnancy or lactation;\n11. Other situations that the researchers believe not suitable for enrollment",{"count":211,"type":20},154,[53],"A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy",[27],"2025-05-28",{"date":217,"type":33},"2025-06-03",{"date":219,"type":33},"2024-07-09",{"date":221,"type":20},"2027-06-30",{"name":201,"class":71},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":132},"100391429","phase-3-toripalimab-for-local-regional-recurrent-nasopharyngeal-carcinoma-100391429","NCT04376866","Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma","Toripalimab in Combination With Concurrent Chemoradiotherapy for Local-regional Recurrent Nasopharyngeal Carcinoma: a Phase 3, Multicentre, Randomised Controlled Trial","Inclusion Criteria:\n\n1. Patients with newly histologically confirmed recurrent nasopharyngeal carcinoma, or Two or more image examinations (MRI, and PET-CT) show the recurrent tumor\n2. staged as rT3-4N0-1M0或rT1-4N2-3M0 （according to the 8th AJCC edition）\n3. Satisfactory performance status: ECOG (Eastern Cooperative OncologyGroup) scale 0-1\n4. Neutrophil ≥ 1.5×109 \u002FL and PLT ≥4×109 \u002FL and HGB ≥90 g\u002FL\n5. With normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN)\n6. With normal renal function test ( creatinine clearance ≥60 ml\u002Fmin)\n7. sign an \"informed consent form\n8. Male and no pregnant female\n\nExclusion Criteria:\n\n1. Age older than 65, or younger than 18 years old\n2. Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥200IU\u002Fml, or 1000cps\u002Fml.\n3. Patients with positive HCV antibody.\n4. Active, known or suspected autoimmune disease; Type I Diabetes, hypothyroidism those only need hormone replacement therapy, and skin disease (leukoderma, psoriasis, alopecia et al) who don't need systemic therapy can recruit.\n5. History of interstitial lung disease\n6. Equivalent dose more than prednisone 10mg\u002Fd or other immunosuppressive treatments within 28 days prior to signing the informed consent.\n7. Receive or will receive live vaccine within 30 days prior to signing the informed consent.\n8. Women of child-bearing potential who are pregnant or breastfeeding.\n9. Suffered from malignant tumors, except the carcinoma in situ, papillary thyroid carcinoma, or skin cancer (non- melanoma) within five years.\n10. Hypersensitivity to macromolecular protein, or to any component of triplezumab.\n11. HIV positive.\n12. Severe, uncontrolled medical conditions and infections.\n13. Other diseases which may influence the safety or compliance of the clinical trial, such as heart failure with symptom, unstable angina, myocardial infarction, active infections those need systemic therapy, mental illness, or their family and society factors.","65 Years",{"count":232,"type":20},204,[53],"This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.",[27],[27,237,238],"Toripalimab","Concurrent chemoradiotherapy","2021-07-18",{"date":241,"type":33},"2021-07-20",{"date":243,"type":33},"2020-06-28",{"date":245,"type":20},"2028-04",{"name":247,"class":71},"Cancer Hospital of Guangxi Medical University",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":255,"targetDuration":4,"studyType":21,"phases":257,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":98},"100379049","phase-3-early-recurrent-nasopharyngeal-cancer-the-effect-of-surgery-vs-imrt-100379049","NCT04215510","Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT","A Multicenter Randomized Controlled Trial for Comparing Endonasal Surgery and Radiation Therapy (IMRT) for T1-T2 Recurrent Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Diagnosed of recurrent nasopharyngeal carcinoma by pathology or imaging study;\n2. Stage T1 or T2 according to AJCC 8th edition ;\n3. Aged 18 to 70 years;\n4. Without metastasis;\n5. previously received 1 course of radiotherapy;\n6. Without radiotherapy within 1 year, without local treatment for recurrent disease;\n7. Surgical resectable and IMRT suitable;\n8. If regional recurrence presented, regional lesion can be treated with local treatments.\n9. ECOG score 0 or 1;\n10. Sufficient organ function;\n11. Acceptable approach of contraception.\n\nExclusion Criteria:\n\n1. Refuse to sign inform consent;\n2. Radiation encephalopathy or leptomeningeal disease (LMD);\n3. History of radioactive particle planting;\n4. Have uncontrolled intercurrent illnesses which will interfere with the ability to undergo therapy;\n5. With prior malignancy (excluding adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer );\n6. Any contradiction to surgery;\n7. Have any co-existing condition that would preclude full compliance or safety with the study;\n8. Presence of a significant neurological or psychiatric disease, including dementia and seizures;\n9. Uncontrolled infectious diseases;\n10. Female patients who are at pregnancy or lactation.\n11. Without personal freedom or independent civil capacity.\n12. With serious autoimmune disease.\n13. Participants of other interventional clinical trial.",{"count":256,"type":20},286,[53],"This study is a multicenter RCT to compare 3-year overall survival(OS) rate, progression free survival(PFS),local progression free survival(LPFS),regional progression free survival(RPFS),distant metastasis free survival(DMFS), and toxicities of endonasal endoscopic surgery versus IMRT.",[27],[261,262,263],"endonasal endoscopic surgery","radiation therapy","nasopharyngeal carcinoma","2021-02-20",{"date":266,"type":33},"2021-02-23",{"date":268,"type":20},"2021-03-01",{"date":270,"type":20},"2027-03-01",{"name":201,"class":71}]